Balancing Hormones and Mental Health: A Psychiatrist’s Guide for Men

Published: 5/10/2026| By: Dr. Baghel | Category: TRT & Men’s Health

Metabolic factors matter too, as in the connection between weight loss and depression.

Peptides marketed for “cortisol optimization” rarely have the human evidence to back the claim; DSIP’s HPA data are mixed, which I cover in my guide to the DSIP peptide.

Most psychiatric workups for men with persistent low mood, blunted motivation, and brain fog look the same. PHQ-9, GAD-7, maybe a TSH, antidepressant trial, return in six weeks. If the antidepressant misses, the next move is usually a different antidepressant.

That next move deserves its own explanation. I cover it in my guide to what to do when your antidepressant isn’t working.

Hormones are one lever in a larger metabolic view of mental health, which I lay out in metabolic psychiatry. For testosterone specifically, see my guide to testosterone therapy for North Carolina men.

Hormones are one contributor to low mood among several. For the full treatment picture, see our guide to depression treatment in North Carolina.

On the female side, a common first question is which premenstrual pattern you have. See PMDD vs PMS.

For a meaningful subset of these men, the missing piece is analyzing hormones and mental health.

If you’re tapering an antidepressant while sorting out hormonal contributors, the drug matters. Our guide to venlafaxine withdrawal covers the hardest one to stop.

Hormones are one driver of sexual function. When sexual symptoms persist after stopping an antidepressant, the cause may sit elsewhere; see our guide to post-SSRI sexual dysfunction.

Federal guidance now urges clinicians to weigh nonmedication and contributing factors before and during treatment. See our read on the MAHA psychiatric overprescribing plan.

I’m a board-certified psychiatrist with subspecialty board certification in forensic psychiatry, running a cash-pay telehealth practice in North Carolina. The patients who land in my practice with treatment-resistant symptoms often have one or more hormonal axes operating outside their personal optimal range. Testosterone is the obvious one. Thyroid, cortisol, and metabolic hormones drive a substantial share of the remaining cases.

This article lays out what hormone-informed psychiatric care actually looks like, what to test, when to test, and how to interpret results in clinical context. It’s written for men weighing whether to seek psychiatric care, men whose current antidepressant isn’t working, and clinicians wondering what a cross-axis approach looks like in practice.

Why a Psychiatrist Cares About Hormones

The standard psychiatric model for depression, the chemical imbalance framing, has been quietly dying in the literature for years. The 2022 umbrella review by Moncrieff and colleagues found no consistent evidence that depression is caused by serotonin deficiency or low serotonin activity (Moncrieff et al., 2023). The serotonin tank model still dominates patient-facing writing, but it doesn’t reflect what’s actually known about depression neurobiology.

That matters for hormones because monoamine theory crowds out other inputs. If depression is a serotonin deficit, then SSRIs are the answer. If depression is the output of a system with multiple regulatory inputs, including the endocrine system, then a standard psychiatric workup is incomplete by design.

Mood is the output of multiple regulatory systems. Hormones interact with mood circuits at the level of androgen receptors in the amygdala and hippocampus, estrogen receptors in the prefrontal cortex, and glucocorticoid receptors throughout the limbic system (Hamson et al., 2016). When these inputs operate outside an individual’s personal optimal range, the felt experience overlaps heavily with what we call major depression.

Most psychiatrists don’t test hormones. Some don’t because residency training emphasized monoamines. Some don’t because insurance won’t pay for a comprehensive panel. Some don’t because they read TRT as a wellness gimmick rather than a clinical tool. Whatever the reason, the gap is real and the patients fall through it.

For men weighing whether to also taper an existing antidepressant alongside a hormonal workup, see the guide to antidepressant discontinuation syndrome for what supervised tapering involves.

The Testosterone-Mood Connection

Testosterone acts on the brain through two parallel routes. It binds androgen receptors directly, and it converts to estradiol via aromatase activity, then binds estrogen receptors. The brain has high androgen receptor density in the amygdala (fear and threat processing), hippocampus (memory and mood), and prefrontal cortex (executive function and motivation) (Tobiansky et al., 2018).

What this means clinically: low testosterone in men commonly produces a symptom cluster that overlaps heavily with atypical depression. Fatigue that doesn’t respond to sleep. Anhedonia. Reduced libido that compounds the mood problem. Brain fog that no neuropsychiatric test captures. Irritability without clear trigger. These are the same symptoms that drive an antidepressant trial.

For men whose depression hasn’t fully responded to antidepressants and who have confirmed low testosterone, the augmentation question is addressed in testosterone augmentation for depression.

The trials supporting testosterone’s mood effect aren’t speculative. A 2019 meta-analysis of 27 randomized controlled trials found testosterone treatment reduced depressive symptoms in men, with the largest effects in subclinical and mild cases (Walther et al., 2019). The effect size was modest, around g = 0.21, but consistent. For men with frank hypogonadism plus depressive symptoms, response rates ran higher.

This is where the differential matters. When a man on an SSRI for six weeks has a flat response, the next move isn’t necessarily a switch to SNRI or augmentation with bupropion. If he’s also reporting low libido, fatigue out of proportion to activity, and reduced morning erections, a fasting morning total testosterone (drawn before 10 AM, repeated to confirm) belongs in the workup. The Endocrine Society defines hypogonadism as total T below 264 ng/dL on two morning samples plus consistent symptoms (Bhasin et al., 2018).

One mistake I see often: treating “low normal” T (the 300-400 ng/dL range) as the cause of depression in a man with concurrent thyroid abnormalities, sleep apnea, or unaddressed substance use will fail. Hormones are one input, not the only one. For men whose anxiety is the dominant symptom rather than depression, see anxiety with hormonal contributors.

Estrogen in Men: The Hormone Most Men Don’t Track

Most men, and most men’s health clinics, frame estrogen as a problem to suppress. That framing misses how estrogen actually works in male physiology.

Estradiol is essential for male bone density, cardiovascular health, libido, and cognition. The Endocrine Society and the European Male Aging Study consistently show that men with E2 below ~20 pg/mL have higher rates of low bone density, sexual dysfunction, and depressive symptoms (Finkelstein et al., 2013). The optimal range is generally 20-40 pg/mL on a sensitive (LC-MS/MS) assay. ECLIA (immunoassay) E2 results in men are often inaccurate at low concentrations and shouldn’t be trusted clinically.

Where estrogen becomes a problem is at the high end. Aromatization of supraphysiologic testosterone, especially in men with elevated body fat, can push E2 well above 50 pg/mL. The clinical picture: mood lability, water retention, anxiety, gynecomastia, and the kind of irritability that gets attributed to “moods” when the trigger is endocrine. For specifics on what to do when this happens on TRT, see estrogen management on TRT.

The opposite problem, aromatase-inhibitor overshoot, is just as real and more common than men realize. Aggressive AI dosing (anastrozole 1 mg daily or more) can crash E2 to single digits, producing joint pain, libido collapse, depression, and cognitive complaints. This is iatrogenic depression dressed up as a TRT side effect. The treatment is to stop or reduce the AI, not to add an antidepressant.

For the broader picture of how testosterone, growth hormone, IGF-1, and estrogen interact in men, see how testosterone, GH, IGF-1, and estrogen interact.

Thyroid: The Quiet Driver of Atypical Depression

Thyroid abnormalities in patients with mood symptoms are one of the most under-tested clinical signals in primary-care psychiatry. The standard “TSH within normal range” reading misses subclinical hypothyroidism, which is associated with depressive symptoms even when free T4 is normal (Joffe & Levitt, 1992). For men presenting with atypical depression, fatigue, weight changes, or cognitive slowing, a TSH alone is inadequate.

The full panel I order: TSH, free T4, free T3, reverse T3, and thyroid antibodies (TPO and thyroglobulin). The reasoning is mechanistic. T4 is the storage hormone; T3 is the active hormone. Conversion (deiodinase activity) varies between individuals and is suppressed by acute stress, inflammation, and caloric restriction. Reverse T3 elevation reflects a body diverting active T3 away under stress. Antibodies flag autoimmune thyroid disease, which can produce mood instability long before frank hypothyroidism shows up on a TSH.

Lab “normal” ranges for TSH typically run 0.4-4.5 mIU/L. The clinical optimum, especially in patients with mood symptoms, is closer to 0.5-2.5. Men whose TSH sits at 3.5 with low-normal free T3 and elevated TPO antibodies are not euthyroid in any meaningful sense, even if every value falls inside the lab’s reference range.

T3 augmentation in treatment-resistant depression has a body of evidence going back decades. The Cooper-Kazaz 2007 trial showed T3 augmentation accelerated and improved response to sertraline in depressed patients (Cooper-Kazaz et al., 2007). Earlier work by Joffe and Sokolov demonstrated T3 augmentation in tricyclic non-responders (Joffe & Sokolov, 1994). T3 isn’t first-line, but it belongs in the algorithm for men whose mood doesn’t lift on standard agents.

Cortisol and the Stress Axis

The hypothalamic-pituitary-adrenal (HPA) axis is the body’s central stress response system, and its dysregulation underlies a large fraction of major depressive episodes. The pattern most people picture is hypercortisolism: chronically elevated cortisol producing the kind of agitated, melancholic depression that responds poorly to standard SSRIs. That’s real, and it’s classically associated with severe major depression (Pariante & Lightman, 2008).

The pattern most psychiatrists miss is the opposite: a blunted cortisol awakening response (CAR) and flat diurnal curve, often seen in atypical depression, chronic fatigue presentations, and post-traumatic conditions. A man whose cortisol fails to rise normally in the morning often presents with profound morning fatigue, low motivation, and a sense that his system is “tapped out.” Single morning serum cortisol won’t capture this. A four-point salivary cortisol curve will.

Chronic high cortisol has structural consequences. Hippocampal volume reduction is one of the most replicated findings in major depression, and animal data link this directly to glucocorticoid exposure (Sapolsky, 2000). For a clinician, cortisol dysregulation acts as a mechanism, driving cognitive complaints and depressive symptoms even when monoamines look untouched.

One clinical pattern worth flagging: men with sleep maintenance insomnia (waking at 2-4 AM and unable to return to sleep) often have an elevated cortisol awakening response. Treating their sleep with trazodone or melatonin without addressing the HPA driver tends to produce partial responses at best. Lifestyle work on stress load, structured exercise, and in some cases adaptogenic or pharmacologic interventions on the HPA axis can move the needle when sleep medications can’t.

The Metabolic Connection: Insulin Resistance and Mood

Metabolic dysfunction and depression share a bidirectional relationship that’s well-documented and routinely ignored in psychiatric practice. Insulin resistance correlates with major depression in multiple large cohort studies, and inflammatory cytokines from metabolic syndrome (IL-6, TNF-α, CRP) cross the blood-brain barrier and activate microglia, producing depressive symptoms via neuroinflammation (Miller & Raison, 2016).

What this looks like in clinic: men with central adiposity, elevated fasting insulin, A1c above 5.7, or fatty liver are often the same men whose depression doesn’t respond to standard SSRIs. The inflammatory environment competes with antidepressant pharmacology, and the metabolic profile itself produces fatigue, anhedonia, and cognitive dulling.

The clinical implication is that a fasting insulin, glucose, A1c, and lipid panel belong in the workup of any man with depression that doesn’t lift on first-line treatment. If insulin resistance is present, addressing it (through structured weight management, GLP-1 medication when appropriate, and resistance training) often produces mood improvement that the antidepressant alone couldn’t deliver.

The GLP-1 agonist signal is worth a separate note. Several recent analyses suggest semaglutide and tirzepatide may produce mood benefits beyond what’s accounted for by weight loss alone, possibly through direct CNS effects on dopamine signaling and inflammation (Wang et al., 2024). The data is preliminary and not yet a basis for prescribing GLP-1s as antidepressants. It does suggest that the metabolic and mood axes are more entangled than older psychiatric models recognize.

When to Test Hormones: A Clinical Decision Framework

The question I get asked most often is when hormone testing should enter the workup. Here’s the framework I use.

High-yield triggers for a comprehensive hormone panel in a man presenting with mood symptoms:

• Treatment-resistant depression (failed two adequate antidepressant trials)
• Atypical depressive features: hyperphagia, hypersomnia, leaden paralysis, mood reactivity
• Sexual symptoms (low libido, erectile dysfunction, reduced morning erections) accompanying mood
• Brain fog or cognitive complaints in men over 35 without another clear cause
• New-onset ADHD-like presentation in adulthood without childhood history
• Sleep maintenance insomnia, especially with early morning awakening
• Significant weight gain, central adiposity, or A1c above 5.7 with mood symptoms
• Family history of thyroid autoimmunity in a man with persistent fatigue

The standard panel I order in this scenario:

• Total testosterone (morning, fasting, repeated to confirm if abnormal)
• Free testosterone, calculated, plus SHBG (the calculation matters more than direct free T immunoassay)
• Estradiol, sensitive LC-MS/MS assay (not standard ECLIA)
• TSH, free T4, free T3, reverse T3, TPO and thyroglobulin antibodies
• Fasting insulin, fasting glucose, hemoglobin A1c
• Lipid panel including ApoB
• AM cortisol or, when chronic stress is suspected, four-point salivary cortisol curve
• Prolactin (rules out a mood-relevant pituitary issue)
• Vitamin D 25-OH, ferritin, B12, folate
• CBC, comprehensive metabolic panel, hsCRP

Interpretation matters as much as the panel itself. Lab “reference ranges” reflect a population distribution, not a clinical optimum. A TSH of 3.8 falls inside the reference range and outside the optimal range for a man with depressive symptoms. A total T of 320 ng/dL falls inside the reference range and below the threshold where most men feel like themselves. Every value gets evaluated against the same clinical question: is this consistent with optimal function for this individual?

If you want this kind of comprehensive workup, book a consultation. The cash-pay structure means I can order the labs that actually answer the clinical question, not the labs your insurance prefers to authorize.

Hormone-Informed Psychiatric Care Defined

Hormone-informed psychiatric care is psychiatry that takes seriously the contribution of testosterone, estrogen, thyroid, cortisol, and metabolic hormones to mood, cognition, and motivation, and incorporates that workup into standard psychiatric assessment and treatment planning. It uses psychiatric medications when indicated. The TRT-as-cure framing some men’s-health clinics promote is a separate model that confuses correction of a deficiency with universal mood treatment.

What it looks like in practice: a comprehensive intake that includes hormonal history alongside psychiatric history. A baseline panel that goes beyond TSH and CBC. Longitudinal monitoring when hormone treatment is initiated, with attention to mood and cognitive endpoints, not just lab numbers. Willingness to treat across axes when clinically indicated, and to refer when a problem falls outside the scope of psychiatric care.

Two boundaries matter in practice. Antidepressants stay in the regimen when symptoms warrant them, regardless of hormone results. Primary psychiatric disorders get pharmacologic treatment whether or not a hormonal contributor is also present. The hormone optimization industry tends to treat lab values as the goal. The clinical goal is a man who functions well across mood, cognition, sleep, libido, and energy. Lab values inform that goal; they don’t define it.

For men exploring peptide options alongside hormone work, particularly for cognition and mood support, see peptide options for cognition and mood. Peptides aren’t a substitute for hormone correction or psychiatric treatment, but they have a defined role in some cases.

Common Mistakes to Avoid

The first mistake is self-managed TRT from a telehealth mill without psychiatric integration. A man with bipolar II who starts testosterone without a baseline mental health assessment risks a hypomanic switch. A man with PTSD whose hyperarousal worsens on TRT needs that signal noticed and managed, not dismissed as adjustment to therapy. Mood and cognition need monitoring throughout TRT, and most TRT mills don’t do that.

The second mistake is ignoring estrogen. Men obsess about testosterone numbers and skip E2 entirely, or run E2 on an insensitive assay that gives a misleading result. The optimal E2 range for a man on TRT is roughly 20-40 pg/mL on LC-MS/MS, and missing this number explains a substantial fraction of “TRT didn’t work for my mood” cases.

The third mistake is treating “low normal” total testosterone (300-400 ng/dL) as the primary cause of depression in a man with untested thyroid, unaddressed sleep apnea, untreated insulin resistance, or an unacknowledged substance use pattern. TRT in this context produces a partial response that doesn’t justify the long-term commitment. Address the other contributors first, then revisit testosterone if symptoms persist.

The fourth mistake is skipping the baseline mental health assessment before starting any hormone treatment. PHQ-9, GAD-7, MDQ for bipolar screening, AUDIT-C for alcohol, basic substance use screening. These are five-minute instruments that catch the cases where hormone therapy needs additional psychiatric support. Most TRT clinics skip them.

The fifth mistake is assuming that monitoring on TRT is just labs. Hematocrit, lipid panel, and PSA are necessary. They aren’t sufficient. Mood, sleep, libido, cognition, and overall functioning are the clinical endpoints. For more on the cardiovascular and hematocrit side of monitoring with psychiatric integration, see TRT monitoring with psychiatric integration.

What to Expect from Hormone-Informed Care in NC

Baghel Psychiatry runs as a cash-pay telehealth practice serving patients across North Carolina. The clinical model is a flat $250/month membership that covers psychiatry, TRT, medical weight loss, and peptide therapy when clinically appropriate. Labs and medications are paid separately. There’s one price and no tiers, billed month to month with no contract.

Cash-pay matters here because insurance billing structures don’t reimburse the kind of comprehensive hormone workup that hormone-informed psychiatric care requires. A 15-minute med-check visit can’t deliver a thorough assessment. A workup that orders the right labs, interprets them in clinical context, and adjusts treatment longitudinally doesn’t fit insurance authorization patterns.

I’m board-certified in adult psychiatry and forensic psychiatry by the American Board of Psychiatry and Neurology. The forensic credential is a stated fact about my training, not a marketing claim about your treatment. It does mean my approach to psychiatric assessment is built on evidentiary discipline, which translates into the kind of citation-grounded, mechanism-aware care this article describes. For TRT under psychiatric supervision specifically, see the TRT under psychiatric supervision service page.

Frequently Asked Questions

Can low testosterone cause depression by itself?

It can, in cases of frank hypogonadism with documented low T and consistent symptoms. More often, low testosterone contributes to a depressive picture alongside other factors (thyroid, sleep, metabolic, psychosocial). The useful clinical question is what fraction of this man’s symptoms is hormonally driven, and what changes when we correct it. Walther et al. 2019 found testosterone treatment reduced depressive symptoms in men with low T, with the strongest effects in subclinical and mild cases.

Do I need to stop my antidepressant before testing hormones?

No. SSRIs and SNRIs don’t meaningfully alter testosterone, thyroid, or cortisol panels in a way that invalidates testing. Bupropion is similarly fine. The only common psychiatric medications that can shift hormonal labs are second-generation antipsychotics (which can elevate prolactin) and lithium (which can affect thyroid function over time). Always test before changing treatment, then re-test if treatment changes.

What labs should I bring to a first appointment?

Any recent CBC, comprehensive metabolic panel, lipid panel, TSH, hemoglobin A1c, and (if available) vitamin D, total testosterone, and ferritin from the past 12 months. If you’ve been on TRT, bring all monitoring labs from the past 24 months including hematocrit, PSA, and any estradiol values. If you’ve never had hormones tested, that’s fine. We’ll order the right panel at the first visit.

Is hormone-informed psychiatric care covered by insurance?

Baghel Psychiatry is a cash-pay practice and does not bill insurance. PPO and POS patients can submit a superbill for potential out-of-network reimbursement; coverage varies by plan. HSA and FSA accounts are accepted. Lab orders go through your preferred lab; many labs accept insurance directly even when the clinician doesn’t.

Can you treat both TRT and depression in one practice?

Yes. That’s the integration the cash-pay model is built around. The $250/month flat rate covers psychiatric medication management and TRT under one clinician, with shared monitoring and a single longitudinal record. For men whose depression and hypogonadism are both contributing to the picture, this avoids the fragmented care that comes from one doctor managing TRT and a different one managing antidepressants. For men whose presentation also touches fertility considerations, see TRT and fertility considerations.

How long before I see mood changes if hormones are part of the problem?

It depends on which axis is involved. Thyroid corrections (with T3 augmentation in TR-depression) can produce mood changes within 2-3 weeks. Testosterone changes typically take 6-12 weeks for full mood effects, longer for cognitive complaints. Cortisol pattern changes from lifestyle and HPA-targeted interventions usually show by week 4-8. If a hormonal correction has been in place for 12 weeks at appropriate target levels and mood hasn’t moved, the contributor probably wasn’t primarily hormonal and the workup needs to widen.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented should not be used to diagnose or treat any medical condition without consultation with a qualified clinician. Hormone testing and treatment require individualized clinical assessment. Treatment decisions should be made in partnership with a licensed physician familiar with your medical history.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364.
2. Cooper-Kazaz R, Apter JT, Cohen R, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2007;64(6):679-688. PMID: 17548749.
3. Finkelstein JS, Lee H, Burnett-Bowie SAM, et al. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. N Engl J Med. 2013;369(11):1011-1022. PMID: 24024838.
4. Hamson DK, Roes MM, Galea LAM. Sex Hormones and Cognition: Neuroendocrine Influences on Memory and Learning. Compr Physiol. 2016;6(3):1295-1337. PMID: 27347894.
5. Joffe RT, Levitt AJ. Major depression and subclinical (grade 2) hypothyroidism. Psychoneuroendocrinology. 1992;17(2-3):215-221. PMID: 1438647.
6. Joffe RT, Sokolov ST. Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol. 1994;8(1-2):45-63. PMID: 7907740.
7. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. PMID: 26711676.
8. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28(8):3243-3256. PMID: 35854107.
9. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31(9):464-468. PMID: 18675469.
10. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57(10):925-935. PMID: 11015810.
11. Tobiansky DJ, Wallin-Miller KG, Floresco SB, Wood RI, Soma KK. Testosterone and Corticosterone in the Mesocorticolimbic System of Male Rats: Effects of Gonadectomy and Caloric Restriction. Endocrinology. 2018;159(1):450-464. PMID: 29069392.
12. Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(1):31-40. PMID: 30427999.
13. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176. PMID: 38182782.